Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KITE-718
- Development stage
- Phase 2
- Lead developer
- Kite Pharma
- Modality
- Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
KITE-718 is an investigational autologous T-cell receptor (TCR)-based cell therapy developed by Kite Pharma (a subsidiary of Gilead Sciences) for the treatment of solid tumors. The therapy involves engineering a patient's own T cells to express a specific TCR that targets the cancer antigens MAGE-A3 and MAGE-A6, which are expressed in various solid tumors. Upon infusion, these modified lymphocytes recognize and kill tumor cells presenting these antigens in the context of HLA-DPB1*04:01. The approach builds on proof-of-concept work from the National Cancer Institute and incorporates next-generation manufacturing technologies to optimize efficacy and safety. KITE-718 was evaluated in Phase 1 clinical trials for advanced cancers but development has been discontinued[1][2][4][5].
- Other names
- MAGE-A3/A6 T cell receptor engineered T cells - Kite PharmaMAGE-A3/A6 TCR engineered T lymphocytes - Kite Pharma
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on KITE-718.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KITE-718.